The 2026 annual meeting of the Society of Hematologic Oncology (SOHO) is quickly approaching. From September 9 through September 12, in Houston, Texas, the SOHO 2026 Annual Meeting is four days of in-person and virtual sessions, lectures, and presentations on all topics related to leukemias, lymphomas, myeloma, and more.

Today, we’re highlighting some of the sessions focusing on topics related to leukemia. Session times and dates are accurate as of August 5, 2026. There are currently only two scheduled sessions for Tuesday, September 8. View the full program on the official SOHO 2026 Annual Meeting website for the most up-to-date information.

Leukemia Sessions at SOHO 2026

Tuesday, September 8

  • Acute Myeloid Leukemia – Practical Strategies for Optimizing Outcomes
    • 4:10 PM – 5:10 PM
    • Description: This is part two of a two-part session taking place on Tuesday. The first session focuses on myelodysplastic syndromes, while this session is focused on acute myeloid leukemia. The session will discuss topics including choosing the right induction therapy, assessment and interpretation of MRD testing in AML, and more.

Wednesday, September 9

  • AML - Menin Inhibition
    • 7:00 AM – 7:45 AM
    • Description: This session features an overview of menin inhibitors in KMT2Ar, NPM1m and other HOX expression leukemias, along with discussions on ongoing trials and mechanisms of resistance.
  • ALL - Case Studies
    • 7:00 AM – 7:45 AM
    • Description: This session features discussions on CAR T in T-ALL, monitoring Ph-Positive ALL, and research in ABL-Class ALL.
  • CML: RW Data and LMIC Collaboration
    • 7:00 AM – 7:45 AM
    • Description: This session includes discussion on improving care in low- and middle-income countries, possible tolerability strategies, and RW data in registries and national agencies.
  • Clinical Management of Early CLL
    • 7:00 AM – 7:45 AM
    • Description: This session features discussion on when to start therapy in CLL, how to choose therapy in CLL, and supportive care in CLL before, during, and after therapy.
  • Advances in ALL
    • 8:00 AM – 8:45 AM
    • Description: Discussion in this session will focus on ALL with myeloid mutations, when to transplant in 2026, and menin inhibitors in ALL.
  • CML - Biological Aspects
    • 8:00 AM – 8:45 AM
    • Description: This session features discussion on CML with atypical transcripts, protein biomarkers to predict blast crisis and durable TFR in CML, and monitoring standards and new approaches.
  • Session I: Acute Lymphoblastic Leukemia
    • 9:15 AM – 11:56 AM
    • Description: This session features discussion on the management of resistant B-ALL, CAR T-cell therapy, optimal management of Philadelphia-positive ALL, and more.
  • Session III: Acute Myeloid Leukemia
    • 3:56 PM – 6:30 PM
    • Description: During this session attendees will hear from the experts on topics including menin inhibitors, FLT3 combinations in frontline and relapse, transplant decisions for AML based on MRD, and more.

Thursday, September 10

  • Session V: Chronic Myeloid Leukemia
    • 10:35 AM – 12:27 PM
    • Description: Topics include advantages and pitfalls of STAMP, the role for allogenic transplant in CML, and more.
  • Session VII: Chronic Lymphocytic Leukemia
    • 5:06 PM – 7:04 PM
    • Description: This session features discussion on defining refractory CLL, immunotherapy in CLL, and more.

Friday, September 11

  • Breakfast With the Expert II
    • 6:45 AM – 7:45 AM
    • Description: This session is a discussion on managing complications of modern treatment strategies in AML.

Saturday, September 12

  • Session XIII: Cellular Therapy
    • 8:15 AM – 10:25 AM
    • Description: This session features pro/con debates on topics including “Should we transplant TP53 Mutated AML” and “In Pediatric ALL will there still be a role for Allo SCT?”
  • Session XIV: Next Questions
    • 10:25 AM – 12:50 PM
    • Description: This session features designated sections for each main discussion category from the conference, including ALL, AML, CLL, and CML. 

Check out our other oncology-related content and be sure to sign up for alerts and stay informed on the latest clinical guidelines and guideline updates.